TrialWorld journal of hepatology2025

Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients.

Veerendra Kumar Panuganti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.